期刊
ARCHIVES OF DISEASE IN CHILDHOOD
卷 99, 期 6, 页码 505-510出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/archdischild-2013-304601
关键词
-
类别
资金
- Medical Research Council [MR/K010239/1] Funding Source: Medline
- MRC [MR/K010239/1] Funding Source: UKRI
- Medical Research Council [MR/K010239/1] Funding Source: researchfish
Aim To review the efficacy and tolerability of pegylated interferon-a and ribavirin for treatment of chronic hepatitis C (CHC) in children in the UK. Methods Retrospective review of children treated for CHC in 3 UK paediatric specialist liver centres between 2005 and 2010. Data on viral response to treatment, demographic and clinical details were collected. Treatment outcome was assessed by the absence of detectable viral RNA in blood 24 weeks after treatment-sustained viral response (SVR). Results 75 children were included; 34 genotype 1; 39 genotypes 2 and 3; 2 genotype 4. Overall SVR was achieved in 54/71 (76%); 65% genotype 1; 89% genotypes 2 and 3; 100% genotype 4. Early response at 12 weeks was achieved in 53 and sustained in 47 (89%). Data on rapid response after 4 weeks of treatment were available in 25; 17/25 (68%) responded and 16 of these (94%) achieved SVR. IL28 T/T genotype was associated with higher SVR. There were no significant changes in weight and height z scores from baseline compared with 24 weeks post-treatment follow-up. No child discontinued treatment due to side effects, although 43 required dose modification. Treatment affected quality of life (QoL) in the initial 12 weeks of treatment, which improved by the end of treatment. Conclusions Children respond well to therapy for CHC. Treatment was tolerated with minimal impact on QoL and no significant effect on growth. Knowledge of viral and IL28 genotypes and early viral response is useful to plan treatment in children and provide appropriate counselling.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据